• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Elevated Lipoprotein (a) Does Not Predict Long-Term Mortality After Heart Attack

by
November 17, 2026
in Health
Reading Time: 5 mins read
0
Elevated Lipoprotein (a) Does Not Predict Long-Term Mortality After Heart Attack

Elevated Lipoprotein (a) Does Not Predict Long-Term Mortality After Heart Attack

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Elevated circulating concentrations of lipoprotein (a) do not correlate with an increased risk of long-term all-cause mortality among individuals who have survived an acute myocardial infarction, according to an extensive prospective cohort study with up to twenty-seven years of longitudinal observation. Lipoprotein (a), often designated Lp(a), is an established, predominantly genetically determined variant of low-density lipoprotein that carries apolipoprotein (a) and possesses pronounced pro-inflammatory and atherogenic characteristics. While elevated plasma concentrations of this lipid particle have been robustly identified as an independent causal risk factor for the initial manifestation of coronary artery disease and acute coronary events across diverse demographic groups, its subsequent influence on survival once cardiovascular disease has clinically manifested has remained a subject of substantial medical debate.

The investigation utilized clinical records and specimen archives from the Augsburg Myocardial Infarction Registry, a population-based framework established in 1984 that systematically records hospital admissions for acute myocardial infarction and prehospital coronary deaths among residents within the Augsburg study region of southern Germany. Eligible participants in the present analysis were individuals younger than sixty years of age who had survived a hospitalized heart attack and subsequently enrolled in a standardized follow-up examination within the KORA Family Heart Study during 1996 and 1997. Because of this enrollment schedule, the median duration between the index cardiac event and the physical study examination stood at 6.2 years, with an interquartile range extending from 2.3 to 9.2 years. To establish family-based comparative references, the study protocols additionally enrolled 545 biological siblings who had no documented history of acute myocardial infarction and subjected them to an identical sequence of clinical examinations, structured personal interviews, and laboratory evaluations.

During the baseline examinations in 1996 and 1997, trained medical staff performed comprehensive physical assessments, which encompassed standardized blood pressure measurements taken in triplicate with a random-zero sphygmomanometer, two-channel Holter electrocardiograms, and cardiac echocardiography performed by an experienced physician. Plasma concentrations of lipoprotein (a) were determined directly from freshly processed venous samples using an automated latex-enhanced immunoassay, with values reported in milligrams per deciliter rather than nanomoles per liter because conversion ratios fluctuate considerably among individual patient phenotypes. Total cholesterol and supernatant cholesterol were quantified via precipitation and enzymatic photometric methods to compute serum low-density lipoprotein cholesterol, alongside standardized quantification of serum creatinine and high-sensitivity C-reactive protein.

To evaluate vital status over an unprecedented observation window, the investigative team completed a comprehensive mortality follow-up in November 2025 by cross-referencing regional civil registration databases. Study participants remaining alive at that time point were administratively censored as of late November 2025, while individuals whose specific residences could not be tracked were censored on the final date their vital status could be confirmed. Over a median observation span of 18.2 years for the post-infarction cohort, and 23.1 years across the entire evaluated cohort, the overall mortality incidence rate among heart attack survivors was recorded at 43.4 deaths per 1000 person-years. Among their unaffected biological siblings, the corresponding incidence rate was 18.8 deaths per 1000 person-years, yielding an unadjusted incidence rate ratio of 2.31 that clearly illustrates the heightened long-term mortality burden experienced by coronary patients.

After excluding eighty-two individuals who lacked complete vital status documentation, the definitive statistical analysis incorporated 617 heart attack patients and 487 biological siblings. The mean age of the post-infarction group was 56.6 years, with male participants accounting for 87.2 percent of that cohort, whereas the sibling comparison group exhibited balanced gender representation and a slightly younger mean age of 55.0 years. Heart attack survivors exhibited significantly higher median baseline lipoprotein (a) concentrations than their siblings, registering 17.0 milligrams per deciliter compared with 13.0 milligrams per deciliter. Among the myocardial infarction cohort, 167 individuals, representing 27.1 percent, demonstrated elevated concentrations defined as at least 50 milligrams per deciliter. Interestingly, patients with elevated concentrations were on average slightly younger and exhibited a significantly lower prevalence of diagnosed diabetes mellitus than those with lower concentrations, while remaining comparable regarding blood pressure, lipid profiles, and medication usage.

Survival probabilities compared across categorical strata using unadjusted Kaplan-Meier curves and log-rank testing revealed no statistically significant divergence in long-term all-cause mortality between heart attack survivors with lipoprotein (a) concentrations of 50 milligrams per deciliter or higher and those with concentrations below that clinical cutoff value. The unadjusted survival curves remained closely aligned across the entirety of the twenty-seven-year follow-up period, producing a non-significant log-rank p-value of 0.273. Within the subgroup presenting with concentrations of at least 50 milligrams per deciliter, the recorded mortality rate was 40.5 deaths per 1000 person-years, compared with 44.4 deaths per 1000 person-years among individuals with lower concentrations, corresponding to an unadjusted rate ratio of 0.91 and indicating no baseline survival penalty attributable to elevated particle concentrations.

To adjust rigorously for potential confounding variables, researchers modeled continuous lipoprotein (a) measurements using restricted cubic splines with four knots within multivariable Cox proportional hazards regressions that adjusted for chronological age, biological sex, smoking status, body mass index modeled with linear and quadratic terms to reflect non-linear mortality relationships, documented diabetes mellitus, left-ventricular ejection fraction, and active lipid-lowering pharmacological therapy. When lipoprotein (a) was analyzed as a dichotomous exposure variable at the standard 50 milligrams per deciliter threshold, the fully adjusted Cox regression model yielded a hazard ratio of 1.04, with a 95 percent confidence interval spanning 0.84 to 1.28 and a p-value of 0.734. Applying continuous spline modeling similarly demonstrated a flat risk profile across the full spectrum of measured values, confirming that circulating concentrations do not predict post-infarction all-cause mortality.

The researchers conducted a series of advanced sensitivity analyses to verify the stability of their primary conclusions against potential methodological artifacts and competing physiological mechanisms. A Cox model incorporating additional adjustments for baseline serum creatinine, low-density lipoprotein cholesterol, and arterial hypertension produced hazard ratios virtually identical to the primary findings. Excluding patients who died within the initial two years following physical examination did not alter the estimates, suggesting that reverse causation did not meaningfully distort the findings. Furthermore, specialized survival models accounting for left-truncation—specifically attained-age and time-since-infarction delayed-entry models—corroborated the lack of association. Multiplicative interaction testing showed no effect modification by diabetes or low-density lipoprotein cholesterol, while an apparent interaction with continuous C-reactive protein lacked directional consistency across spline coefficients. Additive hazard modeling and relative excess risk calculations similarly confirmed the absence of meaningful synergistic interactions.

To leverage the unique family design, the authors analyzed clustered survival outcomes across the combined cohort of 617 heart attack patients and 487 biological relatives using shared-frailty mixed Cox regression models adjusted for identical covariables along with personal history of myocardial infarction. This mixed-case comparative approach yielded an adjusted hazard ratio of 1.09, with a 95 percent confidence interval ranging from 0.91 to 1.31 and a p-value of 0.356, further verifying the absence of excess mortality risk among participants with lipoprotein (a) concentrations equal to or exceeding 50 milligrams per deciliter. Moreover, an isolated evaluation of the sibling group without prior infarction demonstrated that circulating concentrations were not associated with all-cause mortality within that non-infarction sample, demonstrating consistency across individuals sharing close genetic and environmental backgrounds.

The investigative team noted several physiological considerations and methodological limitations that contextualize their results. First, the study examined all-cause mortality rather than recurrent cardiovascular events or cause-specific cardiovascular death because original participant consent restricted access to official death certificates. Second, enrolling patients who survived an average of six years after their initial infarction introduces inevitable survivorship bias, as patients with exceptionally high particle concentrations and lethal acute complications may have died prior to study recruitment. The study also lacked repeated biomarker measurements, precise ethnic diversity data, and records regarding acute revascularization procedures such as percutaneous coronary interventions. A post-hoc statistical power evaluation indicated that while the cohort possessed more than 77.9 percent statistical power to identify hazard ratios of 1.4 or greater, power fell below 50 percent for subtle hazard ratios around 1.2.

Subject of Research: Association between plasma lipoprotein (a) concentrations and long-term all-cause mortality in myocardial infarction survivors

Article Title: Plasma lipoprotein (a) and long-term all-cause mortality in myocardial infarction survivors: a cohort study

Article References: Schmitz, T., Linseisen, J., & Meisinger, C. (2026). Plasma lipoprotein (a) and long-term all-cause mortality in myocardial infarction survivors: a cohort study. Lipids in Health and Disease, 25(1), Article 227. https://doi.org/10.1186/s12944-026-03111-0

Image Credits: AI Generated

DOI: 10.1186/s12944-026-03111-0

Keywords: lipoprotein (a), myocardial infarction, all-cause mortality, Augsburg Myocardial Infarction Registry, KORA Family Heart Study, cardiovascular epidemiology, coronary artery disease, survival analysis, Cox proportional hazards, restricted cubic splines, lipid lowering therapy, apolipoprotein (a), delayed-entry models, survivorship bias, Kaplan-Meier survival, C-reactive protein, low-density lipoprotein

News Source: Ophelia Keating. (November 17, 2026). Elevated Lipoprotein (a) Does Not Predict Long-Term Mortality After Heart Attack. Scienmag.

Tags: all-cause mortalityapolipoprotein (a)Augsburg Myocardial Infarction RegistryC-reactive proteinCardiovascular epidemiologyCoronary artery diseaseCox proportional hazardsdelayed-entry modelsKaplan-Meier survivalKORA Family Heart Studylipid-lowering therapylipoprotein (a)low-density lipoproteinMyocardial Infarctionrestricted cubic splinessurvival analysissurvivorship bias
Share12Tweet7Share2ShareShareShare1

Related Posts

BTN3A3 Downregulation Across Multiple Cancers Points to Potential Metastatic Biomarker

BTN3A3 Downregulation Across Multiple Cancers Points to Potential Metastatic Biomarker

November 17, 2026
Elevated Stress Hyperglycemia Ratio Not Independently Linked to Acute Kidney Injury Risk

Elevated Stress Hyperglycemia Ratio Not Independently Linked to Acute Kidney Injury Risk

November 17, 2026

Targeted Psoriasis Biologics Reshape Immune-Adipose Crosstalk and Suppress Inflammatory Visfatin

November 17, 2026

Wastewater Genomics Detects SARS-CoV-2 Mutations Months Before Clinical Identification

November 17, 2026

POPULAR NEWS

  • Orthognathic Mixed Reality Templates Show Sub-Two-Millimeter Deviations in Early Scoping Review

    Orthognathic Mixed Reality Templates Show Sub-Two-Millimeter Deviations in Early Scoping Review

    29 shares
    Share 12 Tweet 7
  • Iron Oxide Nanoparticles Alleviate Cadmium Stress and Accumulation in Atractylodes Lancea

    29 shares
    Share 12 Tweet 7
  • Elevated Lipoprotein (a) Does Not Predict Long-Term Mortality After Heart Attack

    29 shares
    Share 12 Tweet 7
  • Incremental Deep Learning Reconstruction Improves High-Resolution Coronary CT Angiography Image Quality

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Mirabilis Jalapa Extracts Modulate Optical Band Gap in Polyvinyl Alcohol Films

BTN3A3 Downregulation Across Multiple Cancers Points to Potential Metastatic Biomarker

Affect-Aware Framework May Improve Relational Grounding in LLM Conversations

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.